Related references
Note: Only part of the references are listed.Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
Hans Skovgaard Poulsen et al.
ACTA ONCOLOGICA (2009)
Temozolomide in malignant gliomas: current use and future targets
J. Lee Villano et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
Santosh Kesari et al.
CLINICAL CANCER RESEARCH (2009)
Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ACNU-based chemotherapy for recurrent glioma in the temozolomide era
Caroline Happold et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
Felix Bokstein et al.
CANCER (2008)
Temozolomide Rechallenge in Recurrent Malignant Glioma by Using a Continuous Temozolomide Schedule The Rescue Approach
James R. Perry et al.
CANCER (2008)
Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)
R. Maron et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma
Ilse Vlassenbroeck et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme
Ramon Martinez et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma
Andrew M. Donson et al.
PEDIATRIC BLOOD & CANCER (2007)
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma
P. Hau et al.
NEUROLOGY (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
A. A. Brandes et al.
BRITISH JOURNAL OF CANCER (2006)
Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
RO Mirimanoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme
J Tuettenberg et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas
MF Paz et al.
CLINICAL CANCER RESEARCH (2004)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens
U Emmenegger et al.
CANCER RESEARCH (2004)
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
G Bocci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Inhibition of angiogenesis by non-toxic doses of temozolomide
H Kurzen et al.
ANTI-CANCER DRUGS (2003)
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
AW Tolcher et al.
BRITISH JOURNAL OF CANCER (2003)
Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: A phase II study
AA Brandes et al.
ONCOLOGY (2002)
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
M Brada et al.
ANNALS OF ONCOLOGY (2001)
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma:: A phase II study
AA Brandes et al.
ANNALS OF ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
